NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $1.67 -0.10 (-5.65%) (As of 12/27/2024 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Palisade Bio Stock (NASDAQ:PALI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Palisade Bio alerts:Sign Up Key Stats Today's Range$1.63▼$1.7750-Day Range$1.40▼$3.9152-Week Range$1.38▼$22.35Volume149,263 shsAverage Volume661,790 shsMarket Capitalization$2.53 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company OverviewPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Read More… Palisade Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks43rd Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalisade Bio has only been the subject of 2 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted67.65% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently increased by 1,610.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted67.65% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently increased by 1,610.04%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentPalisade Bio has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Palisade Bio this week, compared to 2 articles on an average week.Search Interest6 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows1 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.28% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PALI Stock News HeadlinesPalisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory BoardDecember 17, 2024 | globenewswire.comPalisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesDecember 13, 2024 | globenewswire.comMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.December 28, 2024 | Insiders Exposed (Ad)Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesDecember 12, 2024 | globenewswire.com2026 Hyundai Palisade Reveals Boxy Stance And All-New InteriorDecember 7, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)December 5, 2024 | markets.businessinsider.comPalisade's Phase 1 Study Of PALI-2108 Shows No Treatment Related Adversities, Stock DownDecember 3, 2024 | markets.businessinsider.comPalisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated SubjectsDecember 3, 2024 | globenewswire.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $8.85 at the beginning of the year. Since then, PALI stock has decreased by 81.1% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) posted its earnings results on Tuesday, November, 12th. The company reported ($2.32) EPS for the quarter, beating analysts' consensus estimates of ($3.35) by $1.03. When did Palisade Bio's stock split? Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Palisade Bio's major shareholders? Top institutional shareholders of Palisade Bio include JPMorgan Chase & Co. (0.54%). Insiders that own company stock include John David Finley, Thomas Hallam, Donald Allen Williams, Michael John Dawson and Robert J Trenschel. View institutional ownership trends. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings11/12/2024Today12/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$38.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,277.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($13.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-148.51% Return on Assets-115.16% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual Sales$250,000.00 Price / Sales10.11 Cash FlowN/A Price / Cash FlowN/A Book Value$18.29 per share Price / Book0.09Miscellaneous Outstanding Shares1,514,000Free Float1,285,000Market Cap$2.53 million OptionableNot Optionable Beta1.39 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:PALI) was last updated on 12/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Elon’s Dec. 31st Surprise “Super-IPO”?There’s a little-known backdoor way to play Elon’s “Super-IPO”… With as little as $50. Paradigm Press | SponsoredFastest Way To Build Wealth From Trump Stock MELT UPDonald Trump is about to ignite the biggest… and fastest… stock market boom in American history. He will be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.